Introduction
============

The global prevalence of diabetes (among adults aged 20--79 years) is predicted to rise to 642,000,000 by 2,040, according to the latest data from the International Diabetes Federation.[@b1-opth-12-191] One of the most common microvascular complications of diabetes is retinopathy, affecting 10% of diabetic patients.[@b2-opth-12-191] Diabetic macular edema (DME) is the leading cause of visual impairment in diabetic retinopathy (DR) and has a significant impact on quality of life.[@b3-opth-12-191] The pathogenesis of DME is highly complex and not yet fully understood. It has been suggested that in patients with diabetes, hyperglycemia may trigger tissue alterations such as damage to capillary endothelial cells in the retina and blood--retinal barrier breakdown, and one of the key players in this process is vascular endothelial growth factor (VEGF).[@b4-opth-12-191] Both angiogenesis and inflammation have been shown to be involved in the pathogenesis of DME; however, it remains to be clarified whether angiogenesis following VEGF overexpression is a cause or a consequence of inflammation.[@b5-opth-12-191]

Laser photocoagulation had been the standard of care for DME for decades following the Early Treatment DR Study (ETDRS) in the 1980s, but this treatment had limited effectiveness in improving vision.[@b6-opth-12-191] Corticosteroids have been used to treat DME due to their anti-inflammatory and anti-angiogenic effects, but their use is associated with high rates of increased intraocular pressure and cataract.[@b7-opth-12-191],[@b8-opth-12-191] Several large clinical trials have established the efficacy and safety profile of anti-VEGF therapy, which has revolutionized how DME is treated and has become the primary treatment for the condition in the majority of DME patients.[@b9-opth-12-191],[@b10-opth-12-191]

In 2012, ranibizumab (Lucentis^®^; Genentech Inc, San Francisco, CA, USA and Novartis Pharma AG, Basel, Switzerland) became the first anti-VEGF agent approved by the US Food and Drug Administration (FDA) for DME.[@b11-opth-12-191] The efficacy and safety of ranibizumab were demonstrated in the RISE and RIDE Phase III clinical trials, which showed that ranibizumab rapidly and sustainably improved vision over 24 months, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of adverse events.[@b10-opth-12-191] While not approved for ocular use, bevacizumab (Avastin^®^; Roche Pharma AG, Vienna, Austria) has been evaluated in smaller trials such as the BOLT study, which provided evidence supporting long-term use of intravitreal bevacizumab for persistent clinically significant macular edema.[@b12-opth-12-191] Most recently, aflibercept (Eylea^®^; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA and Bayer, Basel, Switzerland) gained FDA approval to treat DME in 2014 with the VIVID and VISTA Phase III clinical trials, which demonstrated significant and sustained superiority of aflibercept over laser photocoagulation.[@b9-opth-12-191],[@b13-opth-12-191] Protocol T, the first head-to-head comparison between the 3 anti-VEGF agents, documented significantly better visual acuity (VA) gains with aflibercept compared with bevacizumab and ranibizumab in DME patients in the first year; in the second year, however, the superiority of aflibercept over ranibizumab in patients with baseline VA of 20/50 or worse was no longer present, and all 3 anti-VEGF agents had similar VA outcomes in patients with baseline VA of 20/40 or better.[@b14-opth-12-191],[@b15-opth-12-191]

While no large clinical trials have been undertaken to investigate the efficacy of switching between anti-VEGF agents, a collection of small studies showed the benefit of converting to aflibercept in patients with suboptimal response to ranibizumab and/or bevacizumab: significant anatomic improvements were observed after the switch, across 6 studies; improvements in VA, however, were limited.[@b11-opth-12-191],[@b16-opth-12-191]--[@b20-opth-12-191]

VA is a measure of the spatial-resolving ability of the visual system, usually under conditions of high contrast.[@b21-opth-12-191] VA assessment is the most commonly employed test within ophthalmic examinations, with the ETDRS chart being the primary choice of method to measure VA in registration trials, and the Snellen chart being the predominant modality for VA assessment in the clinical setting.[@b22-opth-12-191] These charts present a series of black-on-white letters in different sizes with the same contrast against the background. However, VA evaluation alone may be inadequate as the real world consists of not only black and white, but also shades of gray where images blend in with backgrounds. In comparison, contrast sensitivity (CS) determines the smallest amount of contrast required to be able to see a target. It defines the threshold between the visible and invisible. In this case, contrast is not kept constant during the test but is varied so that the minimum level of contrast for seeing a target can be determined.[@b21-opth-12-191] CS is a fundamental aspect of visual performance and measuring CS provides additional information on the quality of vision.[@b23-opth-12-191]

DR has been known to be associated with abnormal and reduced CS.[@b24-opth-12-191],[@b25-opth-12-191] Studies have shown that even in diabetic patients with good VA, CS could be impaired.[@b26-opth-12-191]--[@b28-opth-12-191] CS is thus an important outcome measure and could be considered as an adjunct to standard VA testing for a more complete assessment of visual function in DME patients. The CS test has been proven useful for diagnosing early and advanced DR.[@b24-opth-12-191],[@b26-opth-12-191],[@b29-opth-12-191] It has also grown in popularity as a clinical tool for evaluating the impact of therapy since potential treatment response may not be completely characterized by VA measurement alone.[@b21-opth-12-191]

To better assess the effect of treatment change on patients' overall visual functioning, this study was designed to determine and evaluate changes in CS as the primary outcome measure, and in VA as a key secondary outcome measure, in DME patients following treatment switch to aflibercept from ranibizumab.

Material and methods
====================

This institutional review board (IRB)-approved (IRB Services, Aurora, ON, Canada), prospective, interventional, investigator-masked, open-label, non-controlled, single-center study was conducted at Trimed Laser Eye Center, Barrie, ON in Canada, between June 2016 and April 2017. A total of 40 non-consecutive DME patients with persistent fluid on spectral-domain optical coherence tomography (SD-OCT) following at least 3 consecutive ranibizumab injections in the previous 6 months were switched to aflibercept. The criteria for inclusion and exclusion of participants are listed in [Table 1](#t1-opth-12-191){ref-type="table"}. Subjects received 5 consecutive loading doses of 2 mg (0.05 mL) aflibercept at 4-week intervals (weeks 0, 4, 8, 12, and 16). The dosing protocol matched the recommended treatment posology for DME. All patients completed clinical assessments at baseline and week 20. The primary endpoint was mean change of CS from baseline to week 20. Secondary endpoints were mean change from baseline to week 20 in best-corrected VA (BCVA), central retinal thickness (CRT), and vision-related quality of life. The investigator was masked to the outcomes in the main study endpoints until all patients had completed the study.

CS was measured using the Pelli--Robson test at 1 m. The test uses a chart containing optotypes of constant size and varying levels of contrast.[@b30-opth-12-191] The Pelli--Robson CS chart measures 59×84 cm in size and at the recommended 1 m test distance, all letters subtend 2.8 degrees.[@b31-opth-12-191] Each of the 8 rows in the chart comprises 2 triplets of letters. The 3 letters within each triplet have equal contrast; however, each triplet decreases in contrast across and down the chart.[@b31-opth-12-191]

BCVA was recorded using the Snellen chart and converted to logarithm of minimum angle of resolution (logMAR) equivalents for analysis. CRT was measured using SD-OCT (Heidelberg Spectralis; Heidelberg Engineering Inc., Vista, CA, USA). Vision-related quality of life was assessed using the National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) questionnaire with composite score.

Statistical data analysis was performed once all patients had completed the week 20 visit using R version 3.4.0.[@b32-opth-12-191] Visual statistical analyses included mean change in BCVA and CS comparing week 20 to baseline. Anatomic statistical analyses included mean change in CRT at week 20 compared with baseline. A 2-sided paired *t*-test was used to compare the means of continuous variables. If not otherwise stated, all values are presented as mean ± SD. A *P*-value \<0.05 was considered statistically significant.

The study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with Good Clinical Practice and applicable regulatory requirements. The study procedure and informed consent document were approved by IRB Services prior to initiating the study. Written informed consent was obtained from all participants before study enrollment.

Results
=======

Characteristics of study population
-----------------------------------

A total of 50 eyes from 40 patients were included in the study. The mean age of the patients was 70.3±11.3 years, and most were male (65%; [Table 2](#t2-opth-12-191){ref-type="table"}). A mean of 21.1±11.9 (range 5--55) ranibizumab injections, with a mean treatment duration of 30.1±16.5 months, were administered prior to initiation of aflibercept treatment. The mean number of ranibizumab injections in the previous 6 months before the switch to aflibercept was 5.5 (range 5--6). No patients were lost to follow-up, and there were no treatment discontinuations. No ocular or nonocular adverse events were reported in the patient population during the study.

Measures of visual function and anatomic outcomes
-------------------------------------------------

Mean CS increased from 1.40±0.14 log units at baseline to 1.46±0.15 log units at week 20 (*P*\<0.001; [Figure 1](#f1-opth-12-191){ref-type="fig"}). VA also improved over the study period with mean logMAR BCVA of 0.33±0.19 at baseline compared with 0.28±0.16 at week 20 (*P*=0.0016; [Figure 2](#f2-opth-12-191){ref-type="fig"}). There was a statistically significant decrease of 35 µm in mean CRT from 324±85 µm at baseline to 289±61 µm at week 20 (*P*\<0.001; [Figure 3](#f3-opth-12-191){ref-type="fig"}). A statistically significant relationship between changes in CS and CRT (*r*^2^=0.385, *P*\<0.001; [Figure 4](#f4-opth-12-191){ref-type="fig"}) and BCVA and CRT (*r*^2^=0.092, *P*=0.032; [Figure 5](#f5-opth-12-191){ref-type="fig"}) was also found.

Vision-related quality of life measured using NEI VFQ-25
--------------------------------------------------------

At week 20, 22 of 40 patients (55%) experienced an overall improvement in NEI VFQ-25 composite score compared with baseline; 8 patients (20%) experienced no change, and 10 patients (25%) experienced an overall decrease.

Discussion
==========

Study results have demonstrated the functional and anatomic improvements following treatment switch to aflibercept from ranibizumab in recalcitrant DME patients. A statistically significant improvement was found in the primary outcome, with an average CS change of 0.06 log units from baseline to week 20. In addition to CS, statistically significant including an improvement of 0.05 logMAR in BCVA and a 35 µm reduction in CRT. More than half of the patients indicated an improvement in vision-related quality of life, but the number of patients was too small to evaluate a statistical relationship in subgroups.

It is possible that short-term loss of efficacy might have occurred with anti-VEGF therapy, a phenomenon known in the literature as tachyphylaxis.[@b33-opth-12-191] Case studies reported some improvements in CRT and VA in DME patients switched to ranibizumab following bevacizumab treatment failure.[@b34-opth-12-191] However, aflibercept is structurally distinct from bevacizumab and ranibizumab; as a fusion protein consisting of VEGF-binding portions from the extracellular components of VEGF receptor (VEGFR)-1 and VEGFR-2 fused to the fragment crystallizable portion of immunoglobulin G to form a cytokine trap, aflibercept appears to have a number of theoretical advantages over monoclonal antibody bevacizumab and antibody fragment ranibizumab.[@b35-opth-12-191] Aflibercept has markedly greater binding affinity to VEGF-A than either bevacizumab or ranibizumab: the association rate for aflibercept binding to VEGF-A was orders of magnitude faster than that measured for bevacizumab and ranibizumab in pharmacokinetic studies.[@b36-opth-12-191] Similarly, aflibercept inhibited VEGF-A induced activation of VEGFR-1 and VEGFR-2 more potently than bevacizumab or ranibizumab in cell-based assays.[@b36-opth-12-191] Unlike bevacizumab or ranibizumab, aflibercept also binds to other VEGF family members VEGF-B and, importantly, placental growth factor -- a cytokine that can stimulate angiogenesis and plays a crucial role in the activation and sustainment of the inflammatory switch associated with neo-angiogenesis.[@b37-opth-12-191] It is reasonable to assume that these pharmacologic advantages of aflibercept are at least partially responsible for the data presented here.

Results from our study are consistent with findings from other studies investigating outcomes of switching to aflibercept in patients with recalcitrant DME who had been previously treated with ranibizumab and/or bevacizumab. All of these studies were relatively small, involving between 14 and 50 eyes.[@b11-opth-12-191],[@b16-opth-12-191]--[@b20-opth-12-191] Four studies showed statistically significant anatomic improvements with a mean reduction of 37--134 µm in CRT (*P*\<0.05 for all studies), and statistically significant visual improvements with a mean reduction of 0.05--0.06 logMAR in BCVA or a gain of 3 letters on the ETDRS VA chart (*P*\<0.05 for all studies).[@b16-opth-12-191]--[@b19-opth-12-191] In comparison, 2 studies showed statistically significant anatomic improvements with a mean reduction of 96 and 112 µm in CRT (*P*\<0.05 for both studies), while no statistically significant changes in VA were observed.[@b11-opth-12-191],[@b20-opth-12-191]

It is worth noting that 26 patients (64%) in our study still had persisting fluid on SD-OCT at 6 months following treatment switch to aflibercept. One possible explanation is that patients included in the study were those refractory to previous anti-VEGF therapy; this unique subset of "difficult-to-treat" patients may require longer treatment time to achieve optimal outcomes. The results could also be explained by the chronic nature and insidious development of diabetic complications. DR is caused by ongoing damage to the small blood vessels of the retina.[@b38-opth-12-191] Inner retinal alterations occurring in patients with DME may lead to visual deficiency persisting after treatment despite a favorable anatomic response.[@b39-opth-12-191]

When assessing the relationship between anatomic and visual function response to treatment, we observed a statistically significant relationship between a decrease in CRT and an improvement in CS; in comparison, a relatively weaker relationship between changes in CRT and BCVA was seen. This suggests that the inclusion of CS as a measurable endpoint of visual function may yield a more complete understanding of treatment outcomes than that obtained by using VA measurements alone. A similar study evaluating outcomes in patients with recalcitrant neovascular age-related macular degeneration switched to aflibercept from ranibizumab also used CS as the main visual outcome measure.[@b40-opth-12-191] The study demonstrated an association between improvement in CS and change in CRT, but no relationship between improvement in VA and change in CRT.[@b40-opth-12-191]

An increasing number of studies have indicated that VA often fails to predict the day-to-day visual problems faced by the patients.[@b41-opth-12-191] Although VA testing is helpful in identifying difficulties in seeing detail, much of our routine visual activity involves the detection and discrimination of larger objects in luminance.[@b41-opth-12-191] Many daily visual tasks such as reading, driving, and face recognition are highly dependent on CS, and CS has been shown to be a strong predictor of real-world performance, providing useful independent information in relation to one's visual function, which may not be revealed by VA.[@b21-opth-12-191] For example, a patient with poor CS may be able to easily identify dark letters on a white VA chart. Failure to identify a patient with impaired CS may cause unrecognized and untreated visual problems effecting the patient's day-to-day life. Therefore, it is important to include CS as an additional measure to understand the full impact of vision impairment on everyday life. This may be of particular interest to patients with DME because of the close association between DR and CS: vision deterioration in DR is associated with damage to retinal ganglion cells, and responses delivered by ganglion cells to luminance and chromatic contrast are considered to be related to CS.[@b42-opth-12-191],[@b43-opth-12-191]

We used the Pelli--Robson chart to measure CS in the study; a tool that has been used by researchers for many years and is currently the most widely used method for clinical spatial CS testing.[@b30-opth-12-191] It has good test--retest reliability and relative immunity from varying test conditions.[@b21-opth-12-191] The test is quick and can usually be completed in 3--5 minutes; it is easily administered in a clinical setting, with a 6-letter change in CS equating to a 15-letter (or 3-line) change in VA.[@b21-opth-12-191],[@b44-opth-12-191] It has been shown that Pelli--Robson CS is moderately associated with VA, with several studies indicating that these correlation coefficients are \~0.5--0.6.[@b21-opth-12-191]

Our study is important because it used CS change as the primary efficacy endpoint and the results support the use of CS as an independent parameter for determining treatment outcomes in future clinical studies in DME. The data presented here add to the existing knowledge that the evaluation of change in CS provides valuable additional information and should be considered in conjunction with VA measurement when assessing the effect of new treatment modalities. Furthermore, the study design did not include a washout period, which is not typically employed in clinical practice when considering a switch in pharmaceutical agents; therefore, our study closely mimics clinical practice patterns, offering insight into the impact of treatment change in a real-world setting.

We acknowledge some limitations of the study, which are as follows: lack of a control group, a relatively small sample size, and a short follow-up. Additionally, to investigate possible tachyphylaxis with anti-VEGF therapy, it would be of interest to have a 2-period crossover study design involving a re-switch from aflibercept back to ranibizumab.

Conclusion
==========

Management of DME cases exhibiting suboptimal response to anti-VEGF therapy remains a clinical challenge. Our study provides further evidence of the benefit of switching to aflibercept in patients with recalcitrant DME who had been previously treated with ranibizumab. Converting to aflibercept from ranibizumab in these patients led to positive anatomic and visual function outcomes, resulting in statistically significant improvements in all measured metrics, including CS, VA, and CRT. The majority of patients also indicated an improvement in vision-related quality of life. Future studies involving larger patient populations and longer durations are needed to determine whether these results will be sustained or improve further.

The finding of a stronger relationship between changes in CRT and CS compared with changes in CRT and BCVA suggests that CS may be a clinically meaningful measure of treatment response and could have implications for present and future studies evaluating treatment patterns and novel drug therapies in DME and other retinal diseases. Assessing both VA and CS in clinical studies may provide a more complete picture of the effect of treatment on vision than either measure alone. Wider use of CS as an additional outcome endpoint would offer clinicians important information about the impact of treatment on patients' overall visual functioning.
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![Mean log contrast sensitivity at baseline and week 20.\
**Notes:** \*Indicates the mean value. Difference between mean log contrast sensitivity at week 20 and at baseline was statistically significant: *P*\<0.001.](opth-12-191Fig1){#f1-opth-12-191}

![Mean logMAR best-corrected visual acuity at baseline and week 20. **Notes:** \*Indicates the mean value. Difference between mean logMAR BCVA at week 20 and at baseline was statistically significant: *P*=0.0016.\
**Abbreviations:** BCVA, best-corrected visual acuity; logMAR, logarithm of minimum angle of resolution.](opth-12-191Fig2){#f2-opth-12-191}

![Mean central retinal thickness at baseline and week 20.\
**Notes:** \*Indicates the mean value. Difference between mean CRT at week 20 and at baseline was statistically significant: *P*\<0.001.\
**Abbreviation:** CRT, central retinal thickness.](opth-12-191Fig3){#f3-opth-12-191}

![Change in log contrast sensitivity versus change in central retinal thickness at week 20.\
**Note:** Relationship between change in CS and change in CRT was statistically significant: *P*\<0.001.\
**Abbreviations:** CRT, central retinal thickness; CS, contrast sensitivity.](opth-12-191Fig4){#f4-opth-12-191}

![Change in logMAR best-corrected visual acuity versus change in central retinal thickness at week 20.\
**Note:** Relationship between change in BCVA and change in CRT was statistically significant: *P*=0.032.\
**Abbreviations:** BCVA, best-corrected visual acuity; CRT, central retinal thickness; logMAR, logarithm of minimum angle of resolution.](opth-12-191Fig5){#f5-opth-12-191}

###### 

Inclusion and exclusion criteria

  Inclusion criteria                                 Exclusion criteria
  -------------------------------------------------- ---------------------------------------------------------------------------------------------
  Informed consent                                   Intraocular pressure \>25 mmHg
  ≥18 years of age                                   Prior retinal surgery or significant subretinal scarring, cataracts, or vitreous hemorrhage
  Ability to complete study                          Anti-VEGF treatment within prior 30 days
  ≥3 ranibizumab injections over previous 6 months   Intravitreal steroid treatment within prior 6 months
  Persistent fluid on OCT                            MI, TIA, or CVA within prior 90 days
  Baseline fluorescein angiography                   Current pregnancy or lactation
  VA \>6/30                                          

**Abbreviations:** CVA, cerebrovascular accident; MI, myocardial infarction; OCT, optical coherence tomography; TIA, transient ischemic attack; VA, visual acuity; VEGF, vascular endothelial growth factor.

###### 

Demographics and characteristics of patients at baseline (N=40)

  Subject characteristics                                   Mean   SD     Range
  --------------------------------------------------------- ------ ------ --------
  Age (years)                                               70.3   11.3   41--88
  Previous ranibizumab injection                            21.1   11.9   5--55
  Duration of prior ranibizumab therapy (months)            30.1   16.5   6--68
  Number of ranibizumab injections over previous 6 months   5.5           5--6
  Male (%)                                                  65.0          
